ReviewJournal of experimental & clinical cancer research : CR2021
Pharmacology-based ranking of anti-cancer drugs to guide clinical development of cancer immunotherapy combinations.
Review in Journal of experimental & clinical cancer research : CR, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 3 syntheses or guidelines pooled it, 71 citations in OpenAlex.
- Dose fractionation of CAR-T cells. A systematic review of clinical outcomes.Journal of experimental & clinical cancer research : CR · 2023Pooled it
- Cardiotoxicity of lung cancer-related immunotherapy versus chemotherapy: a systematic review and network meta-analysis of randomized controlled trials.Frontiers in oncology · 2023Pooled it
- Dose-response correlation for CAR-T cells: a systematic review of clinical studies.Journal for immunotherapy of cancer · 2022Pooled it
- Virtual clinical trials of anti-PD-1 and anti-CTLA-4 immunotherapy in advanced hepatocellular carcinoma using a quantitative systems pharmacology model.Journal for immunotherapy of cancer · 2022Trial
- Facile synthesis of amorphous coordinated metal-drug frameworks for cancer immunotherapy.Materials today. Bio · 2026Article
- Targeting T-Cells for Cancer Treatment: Current Clinical Strategies and Challenges.Biomedicines · 2026Review
- VSIG4Journal of experimental & clinical cancer research : CR · 2025Article
- Development of Cell and Gene Therapies for Clinical Use in the US and EU: Summary of Regulatory Guidelines.Current gene therapy · 2025Review
- Machine learning in oncological pharmacogenomics: advancing personalized chemotherapy.Functional & integrative genomics · 2024Review
- Dendritic Pyridine-Imine Copper Complexes as Metallo-Drugs.Molecules (Basel, Switzerland) · 2024Review
- Imaging diagnosis and efficacy monitoring by [Theranostics · 2024Article
- Editorial: Emerging learnings in cell therapy: novel binding domains, universal CAR-T cells, and more.Frontiers in oncology · 2024Article
- Immune checkpoints are predominantly co-expressed by clonally expanded CD4Journal of experimental & clinical cancer research : CR · 2023Article
- Current state and challenges of emerging biomarkers for immunotherapy in hepatocellular carcinoma (Review).Experimental and therapeutic medicine · 2023Review
- Morusin shows potent antitumor activity for melanoma through apoptosis induction and proliferation inhibition.BMC cancer · 2023Article
- Metastatic lymph node targeted CTLA4 blockade: a potent intervention for local and distant metastases with minimal ICI-induced pneumonia.Journal of experimental & clinical cancer research : CR · 2023Article
- Predictive models for response and survival in patients treated with anti-PD-1 monotherapy or with anti-PD-1 and ipilimumab combination: editorial commentary.Annals of translational medicine · 2023Article
- Postoperative adjuvant immunotherapy for high-risk hepatocellular carcinoma patients.Frontiers in oncology · 2023Article
- Current Status in Rechallenge of Immunotherapy.International journal of biological sciences · 2023Review
- Impact of Liver Metastases and Number of Metastatic Sites on Immune-Checkpoint Inhibitors Efficacy in Patients with Different Solid Tumors: A Retrospective Study.Biomedicines · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The success of antibodies targeting Programmed cell death protein 1 (PD-1) and its ligand L1 (PD-L1) in cancer treatment and the need for improving response rates has led to an increased demand for the development of combination therapies with anti-PD-1/PD-L1 blockers as a backbone. As more and more drugs with translational potential are identified, the number of clinical trials evaluating combinations has increased considerably and the demand to prioritize combinations having potential for success over the ones that are unlikely to be successful is rising. This review aims to address the unmet need to prioritize cancer immunotherapy combinations through comprehensive search of potential drugs and ranking them based on their mechanism of action, clinical efficacy and safety. As lung cancer is one of the most frequently studied cancer types, combinations that showed potential for the treatment of lung cancer were prioritized. A literature search was performed to identify drugs with potential in combination with PD-1/PD-L1 blockers and the drugs were ranked based on their mechanism of action and known clinical efficacy. Nineteen drugs or drug classes were identified from an internal list of lead molecules and were scored for their clinical potential. Efficacy and safety data from pivotal studies was summarized for the selected drugs. Further, overlap of mechanisms of action and adverse events was visualized using a heat map illustration to help screen drugs for combinations. The quantitative scoring methodology provided in this review could serve as a template for preliminary ranking of novel combinations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.